Drug Type Small molecule drug |
Synonyms (+)-Daunomycin, (8S-cis)-8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione, Acetyladriamycin + [7] |
Target |
Mechanism Top II inhibitors(Topoisomerase II inhibitors), Apoptosis stimulants, RNA synthesis inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (08 Apr 1996), |
RegulationOrphan Drug (US) |
Molecular FormulaC27H29NO10 |
InChIKeySTQGQHZAVUOBTE-VGBVRHCVSA-N |
CAS Registry20830-81-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Kaposi Sarcoma | FR | 19 Aug 1996 | |
AIDS-related Kaposi Sarcoma | US | 08 Apr 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | US | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | BE | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | CA | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | DK | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | FR | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | IL | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | IT | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | NL | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | ES | 15 Aug 2018 | |
Acute Myeloid Leukemia | Phase 2 | SE | 15 Aug 2018 |
Phase 2 | 17 | fshalkgtyt(gcfxixcpjl) = daahocxqlm ygadceedqp (xypvmzzffh, efixadgxek - ikvbtvbquj) View more | - | 25 Jan 2016 | |||
Phase 2 | 60 | Daunomycin+Cyclophosphamide+leucovorin+Hydrocortisone+6-thioguanine+aminopterin+6-mercaptopurine+dexamethasone+Vincristine+Methotrexate+Cytarabine+L-Asparaginase (Arm 2 High Risk) | nolkrdttuj(tawfjvqqxm) = qruqwznptc hbcxazeegu (wyqwxlpsxn, ffvatywfou - jdxydlpkun) View more | - | 09 Jun 2014 | ||
Daunomycin+leucovorin+Hydrocortisone+6-mercaptopurine+dexamethasone+Methotrexate+Vincristine+Cytarabine+L-Asparaginase (Arm 1 Standard Risk) | xpyoqinryx(bwizmuomjw) = tcjqtstnrx oslfkpbwmk (lfgiqdksmr, fmrfexkldk - ekkdyygvjm) View more | ||||||
Phase 2/3 | 611 | tahmswzmug(octdwcfenu) = okiqzjbfxu gxhipizzva (xqeyjvawtw ) View more | - | 04 Jul 2013 | |||
tahmswzmug(octdwcfenu) = tepnpxmzjp gxhipizzva (xqeyjvawtw ) View more | |||||||
Not Applicable | 21 | rytfleijtr(vgyutaktth) = lvyvcksuob dgvqfyqysl (lkafjqojzd ) | - | 01 Jun 2005 | |||
rytfleijtr(vgyutaktth) = gbdryqtgja dgvqfyqysl (lkafjqojzd ) | |||||||
Not Applicable | 76 | hfukkwxemi(gnltzquhtq) = pancytopenia being the most frequent reported effects umrymqignb (wqhsvvaark ) View more | - | 01 Jan 2004 | |||
(Other treatment options) |